The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How to treat patients with high-risk multiple myeloma

Jun 22, 2020

During the 25th Congress of the European Hematology Association (EHA), the Multiple Myeloma (MM) Hub spoke to Jesús San Miguel, University of Navarra, Pamplona, ES about the management of patients with high-risk MM.

Despite emerging treatments for patients with MM, the prognosis of patients with high-risk cytogenetics remains inferior to those with standard-risk disease. Could early intervention with novel therapies, such as CAR T-cell therapy and bispecific antibodies, improve the outcomes of patients with high-risk MM?

In this interview, Jesús San Miguel discusses the safety and efficacy of the B-cell maturation antigen-targeted CAR T-cell therapy, idecabtagene vicleucel (ide-cel; bb2121), in patients with relapsed/refractory MM.

Clinical management of high-risk multiple myeloma